Kairos Ventures
Early-stage venture investor that backs inventions, patents and companies spun out from universities and academic labs. The firm describes its focus as investing in ideas, patents and businesses from top universities and scientists and supporting entrepreneurs and scientists to move technologies from the lab to the boardroom.
Kairos Ventures
Beverly Hills, California, United States, North America
Services
Equity investment for university spinouts
Provides capital to companies formed from university research and academic inventions (described on the site as investing in university spinouts and ideas, patents and businesses from leading universities and scientists).
Commercialization and go-to-market support for academic founders
Support described as nurturing entrepreneurs and scientists from the lab to the boardroom; assistance aimed at translating academic inventions into commercial businesses.
Portfolio company communications and news distribution
Publishes portfolio news items and press summaries (e.g., regulatory designations and clinical milestones for portfolio companies) on the firm website and aggregates third-party coverage.
Equity investment for university spinouts
Provides capital to companies formed from university research and academic inventions (described on the site as investing in university spinouts and ideas, patents and businesses from leading universities and scientists).
Commercialization and go-to-market support for academic founders
Support described as nurturing entrepreneurs and scientists from the lab to the boardroom; assistance aimed at translating academic inventions into commercial businesses.
Portfolio company communications and news distribution
Publishes portfolio news items and press summaries (e.g., regulatory designations and clinical milestones for portfolio companies) on the firm website and aggregates third-party coverage.
Portfolio
Portfolio company developing AuriNovo™, a patient-specific 3D-bioprinted living tissue ear implant. Reported milestones include Orphan Drug designation (Nov 19, 2019), FDA Rare Pediatric Disease designation (Dec 6, 2019), and a Phase 1/2a first-in-human ear reconstruction procedure and clinical trial (June 2022).
#Regenerative medicine; 3D-bioprinting; biologics/therapeutic implants
Uses medicinal chemistry technology from Caltech and biomarker-driven assays from UCLA to accelerate pre-clinical drug discovery and clinical timelines. Year founded 2017. CEO: David Licata. Board observer: Paul Becker.
#Pharma; pre-clinical drug discovery
Portfolio company developing AuriNovo™, a patient-specific 3D-bioprinted living tissue ear implant. Reported milestones include Orphan Drug designation (Nov 19, 2019), FDA Rare Pediatric Disease designation (Dec 6, 2019), and a Phase 1/2a first-in-human ear reconstruction procedure and clinical trial (June 2022).
#Regenerative medicine; 3D-bioprinting; biologics/therapeutic implants
Uses medicinal chemistry technology from Caltech and biomarker-driven assays from UCLA to accelerate pre-clinical drug discovery and clinical timelines. Year founded 2017. CEO: David Licata. Board observer: Paul Becker.
#Pharma; pre-clinical drug discovery